Lila Tretikov

SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023

Retrieved on: 
Tuesday, August 8, 2023

Gross margin was 67% for the second quarter of 2023 compared with 65% for the second quarter of 2022.

Key Points: 
  • Gross margin was 67% for the second quarter of 2023 compared with 65% for the second quarter of 2022.
  • Adjusted gross margin was 70% for the second quarter of 2023 compared to 67% for the second quarter of 2022.
  • R&D expenses for the second quarter of 2023 were $8.9 million compared to $9.0 million for the second quarter of 2022.
  • Operating loss for the second quarter of 2023 was $20.0 million compared to $24.1 million in the second quarter of 2022.

SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

Retrieved on: 
Wednesday, May 31, 2023

BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023.

Key Points: 
  • BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors.
  • The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023.
  • Artificial intelligence has the potential to create positive change for humanity, and especially in medicine and biology," said Lila Tretikov.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on Twitter , LinkedIn , Facebook , and Instagram .